August 21, 2004
For Immediate Release
Atrial Fibrillation Growing to Reach a $175 Million Market, According to MedMarkets, by MedMarket Diligence
The most commonly treated form of cardiac arrhythmia is atrial fibrillation (AF), stemming from a large patient base, the availability of effective approved systems and ready reimbursement. AF affects more than 2 million Americans, or more than 5% of those over age 65. Growth in ablative treatment of arrythmias is already strong in both open and minimally invasive surgeries, utilizing cryogenics, lasers and radiofrequency, with more products and manufacturers on the horizon.
"Ablation therapy has seen dramatic growth in many clinical applications, and will demonstrate particularly remarkable growth through 2010 and beyond for several types of cardiac arrhythmia," says Patrick Driscoll of MedMarket Diligence, publisher of MedMarkets. "Compound annual growth in excess of 25% will be sustained for ablative treatments of atrial fibrillation, atrial flutter, AV nodal tachycardia, AV reentrant tachycardia, and premature ventricular contractions."
According to Driscoll, despite aggressive growth of ablative technologies in other clinical applications such as general surgical electrosurgery, endometrial ablation and others, the the use of ablative technologies for cardiovascular disease comprise nearly two-thirds of all energy-based products.
The August 2004 issue of MedMarkets reveals the current state of development in ablative technologies for arrhythmia, the revenue shares for active competitors and the growth of the market that is expected through 2013.
More extensive analysis of the arrhythmia ablation market is provided in a report by MedMarket Diligence, updated in March 2004, on "Trends & Opportunities in the U.S. Markets for Ablative Technologeis and Other Energy-Based Therapies." Details of that report are available at http://www.mediligence.com/rpt-s110.htm.
Companies developing ablative systems for treatment of arrhythmia include PLC Medical Systems/Edwards Lifesciences, CryoCath, AtriCure, Boston Scientific, Biosense Webster, St. Jude Medical, Cardima, Bard Electrophysiology, Guidant/AFx, CryoCor, Irvine Biomedical, ProRhythm (Transurgical), MedicalCV and Medtronic.
Also covered in the August issue of MedMarkets is a review of the developments, companies and activities in the area of stem cell therapies, including details on the efforts of thirteen companies pursuing approaches in tissue repair and replacement, drug discovery and screening, functional genomics and correction of genetic defects.
MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries. The company publishes the “MedMarkets” newsletter, a monthly analysis of the market implications of new medical technology and dedicated reports on technology markets. For more information on MedMarket Diligence, LLC, contact Patrick Driscoll at (949) 859-3401, e-mail, or visit http://www.mediligence.com.